¿Por qué la investigación contra el cáncer pulmonar no tiene suficiente financiamiento?

History of immunotherapy as a treatment against pulmonary cancer

The Immunotherapy It is a type of cancer treatment that uses your body’s immune system to eliminate cancer cells and is useful for some people with pulmonary to live more time. According to Sethakorn, immunotherapy has played an important role in cancer treatment in recent years.

In the eighties and nineties, the field of immunobiology was developed, based on an investigation that they made several decades before you suggested that the immunolomogical system Play a role Important in the development of cancer. But Sethakorn said it was not until the early years of the new millennium that the modern immunotherapies with which we are familiar, such as Pmbrolizumab (Keytruda), became relevant.

Immunotherapies were approved for people who received treatment with standard chemotherapy when their cancers returned to sear. The researchers of the researchers so successful clinical outcomes using immunotherapy that the next step was to provide it to people such as their initial pulmonary treatment for bodler.

That also succeeded and immunotherapy was used as first -line treatment For pulmonary cancer, even in advanced stages and is now used to treat Templass Pulmonary Cancer stages.

«Remembering the various groups that did these fundamental investigations of immunobiology gives me a huge sense of humility,» said Sethakorn. «We have had amazing results with the use of more effective drugs, such as these immunotherapies, but that took a few decades.»

The disparisas of the lung cancer financier

I deflected, the Five -year survival rate For lung cancer, the percentage of people who five years after receiving a cancer diagnosis, barely exceeds 1 in 4 people (26.7%).

According to a Study of 2024 From the journal JCO practice of oncology, «the investigation of very very cancers of incidents and mortality rates has not been adequate.» Pulmonary cancer investigations received Apraximadas $ 300 million In subsidies of the National Institute of Health [Institutos nacionales de la salud] (NIH) In 2019. Although that might seem a lot, it is extremely expensive to carry out clinical research and trials. And to have an idea of ​​what this amount of money represents: $ 300 million is less than half of the presumptor that finances the related web sites -with the chalce of prostate and breast. Breast cancer, for example, causes 15% of cancer deaths, but receives more than 20% financing for research.

The inequalities in the diversity of the participants in the son Investigations A problem of problems in regard to the essays and the clinical outcomes in what refers an investigation of the research Relations with the pulmonary song.

He Pragmatic-Lung essay [Pulmonar pragmático] It aims to standardize the design of clinical trials as a result of NIH and FDA efforts [Administración federal de medicamentos] To reduce obstacles to the participation of participation in trials making sea easier for registered patients, than an easy sea sea for researchers to perform Enarayas and that the diversity of the participants increases. «The participation of groups that historical have had little representation, such as black patients, women and Hispanics, agree more with cancer rates of these groups,» Sethakorn explained.

Patient rights defenders work to improve pulmonary song research

Other ways to reduce financing for research Relationship relationships with lung cancer include the work of groups that defend patients’ rights. The defenders of the rights of patients, also known as reviewing colleagues, talk about the benefits and involudes of studies and what the treatments imply. «Our work implies giving visibility to theity and opinion of our groups relationships with cancer,» he said Christina Sisti, DPS, MPHDefender of the rights of cancer patients.

Sisti talks to other people in the community of cancer patients about clinical trials and how people can participate. «I discovered that the Department of Defense and the Institute against Cancer have opportunity related to the defense of the rights of research patients,» said Sisti. The first step for converging in a defender of the rights of research patients, he added, is to respond forms of their websites.

Surveillance records and clinical trials relationships with lung cancer

Clinical trials facilitate an early corner to new promising therapies that has not yet yielded by the FDA according to Sethakorn. «It is the way we, as a medical research community, start an incoming how effective it can be a treatment and that collateral effects must be monitored.»

Records, a different tupo of medical research, do not provide medical dispitis or new treatments. Instead, they focus on the characteristics and information of people who receive cancer diagnoses. For example, they can be useful for responding to cycles.

Ask your oncologist if there are clinical trials in which I was convenient to participate. Frequent you can decrease if there are clinical trials that are looking for participants at the moment. You can also search for Clinicaltrials.gov. Organizations or patient rights defense groups such as American Lung Association [Asociación estadounidense del pulmón] Or American society against cancer also have resources for people to find clinical trials.